Looking ahead, Biogen aims to keep advancing its pipeline and scouting new drug candidates, execs said Wednesday. The company now focuses on multiple sclerosis, SMA and biosims, but it's planning to advance into ophthalmology, movement disorders, neuromuscular diseases, stroke and more in the 2020s, the company said in an investor presentation. It's still fanning its ambitions in pain, Alzheimer's and neurocognitive disorders as well.